(Reuters) – AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland for discovery and development of cell therapies.
More than 150 jobs will be created at the site in the United States to initially focus on manufacturing the cell therapies to enable clinical trials to be conducted, the company said, adding that the site may expand its focus to support other disease areas.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)
Comments